Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

1,25-Dihydroxyvitamin D3 prevents the decrease of bone mineral appositional rate in rats with inflammation-mediated

U G Lempert1, H W Minne, B Albrecht

  • 1Department of Internal Medicine I, Endocrinology and Metabolism, University of Heidelberg, FRG.

Bone and Mineral
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of cilobradine in cats with a first episode of congestive heart failure due to primary cardiomyopathy.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2022
Same author

Effect of different doses of inhaled ciclesonide on lung function, clinical signs related to airflow limitation and serum cortisol levels in horses with experimentally induced mild to severe airway obstruction.

Equine veterinary journal·2019
Same author

Slow cortical potentials neurofeedback in children with ADHD: comorbidity, self-regulation and clinical outcomes 6 months after treatment in a multicenter randomized controlled trial.

European child & adolescent psychiatry·2019
Same author

Efficacy of inhaled budesonide for the treatment of severe equine asthma.

Equine veterinary journal·2018
Same author

Molecular and clinical studies in 8 patients with Temple syndrome.

Clinical genetics·2018
Same author

[Pregnancy and lactation-associated osteoporosis].

Zeitschrift fur Rheumatologie·2017

1,25-dihydroxyvitamin D3 (1,25(OH)2D3) effectively prevents bone loss in inflammation-mediated osteopenia (IMO) in rats at a specific dose and duration. This vitamin D3 form is more potent in enhancing bone mineral apposition when it is impaired.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Inflammation-mediated osteopenia (IMO) is characterized by reduced osteoblast number and impaired bone mineral appositional rate.
  • 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) is a key hormone regulating calcium and phosphate homeostasis and bone metabolism.

Purpose of the Study:

  • To investigate the effects of 1,25(OH)2D3 on bone mass and mineral appositional rate in healthy rats and rats with IMO.
  • To determine the optimal dosage and duration of 1,25(OH)2D3 administration for preventing bone loss in IMO.

Main Methods:

  • Rats were induced with inflammation-mediated osteopenia (IMO).
  • Different daily doses and durations of 1,25(OH)2D3 administration were tested.
  • Bone mass and bone mineral appositional rate were measured in intact and IMO rats.

Related Experiment Videos

Main Results:

  • A daily dose of 25 ng/rat of 1,25(OH)2D3 effectively prevented IMO-specific bone loss when administered over 21 days.
  • Higher doses of 1,25(OH)2D3 were less effective in preventing bone loss.
  • 1,25(OH)2D3 administration prevented the reduction in mineral appositional rate in IMO rats and caused only a moderate increase in intact rats.

Conclusions:

  • 1,25(OH)2D3 is effective in preventing bone loss associated with inflammation-mediated osteopenia.
  • The therapeutic effect of 1,25(OH)2D3 is dependent on both dose and duration of treatment.
  • 1,25(OH)2D3 demonstrates greater efficacy in stimulating bone mineral appositional rate in conditions where it is already impaired, such as in IMO.